Evidence map›Paper›PMID 35600274›Full record

ArticleOpen life sciences2022

NR4A1 inhibits the epithelial-mesenchymal transition of hepatic stellate cells: Involvement of TGF-β-Smad2/3/4-ZEB signaling.

Qian Huang, Jingying Xu, Yanyan Ge, Yue Shi, Fei Wang, Mingli Zhu

Open access · goldAbstract read
In one paragraph

Article in Open life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Qian HuangDepartment of Infectious Diseases, Hangzhou Xixi Hospital, Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310023, China.
Jingying XuDepartment of Infectious Diseases, Hangzhou Xixi Hospital, Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310023, China.
Yanyan GeDepartment of Internal Medicine, Hangzhou Third People's Hospital, Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310009, China.
Yue ShiDepartment of Infectious Diseases, Hangzhou Xixi Hospital, Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310023, China.
Fei WangDepartment of Infectious Diseases, Hangzhou Xixi Hospital, Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310023, China.
Mingli ZhuDepartment of Laboratory Medicine, Hangzhou Xixi Hospital, Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310023, China.
Hangzhou Xixi hospital · CNZhejiang University · CNThird People's Hospital of Hangzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to examine whether nuclear receptor 4a1 (NR4A1) is involved in inhibiting hepatic stellate cell (HSC) activation and liver fibrosis through the epithelial-mesenchymal transition (EMT). HSC-T6 cells were divided into the control group, the acetaldehyde (200 μM, an EMT activator) group, and the NR4A1 activation group (Cytosporone B; 1 μM). The expression levels of the epithelial marker E-cadherin, the mesenchymal markers fibronectin (FN), vimentin, smooth muscle alpha-actin (α-SMA), and fibroblast-specific protein 1 (FSP-1), and the components of the transforming growth factor (TGF)-β pathway were detected by real-time polymerase chain reaction and western blotting. Compared with the control group, E-cadherin in the acetaldehyde group was downregulated, whereas FN, FSP-1, vimentin, α-SMA, and COL1A1/COL1A2 were upregulated (

Indexed as

epithelial–mesenchymal transitionliver fibrosisnuclear receptor 4a1

Identifiers

PMID35600274
PMCPMC9070444
OpenAlexW4285129625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.